Benjamin Oakes, Ph.D.
Co-founder, President, and CEO at Scribe Therapeutics
Benjamin L. Oakes is the co-founder, President, and Chief Executive Officer at Scribe Therapeutics, a molecular engineering company focused on creating best-in-class in vivo therapies that permanently treat the underlying cause of disease. Scribe has built an evergreen CRISPR by Design™ platform for creating custom CRISPR molecules specifically for therapeutic use within the human body. Ben has contributed to over 25 publications and patent applications on topics including synthetic biology, molecular engineering, CRISPR and zinc finger-based genetic modification, and was named to Endpoints 20 Under 40 in biopharma and Business Insider 30 Under 40 transforming healthcare. Previously, as an Innovative Genomics Institute Entrepreneurial Fellow, he focused on the holistic engineering of genome editing technologies to build novel genome editing molecules. Ben received a Ph.D. in Molecular and Cellular Biology from UC Berkeley in 2017, where he worked in the Doudna Lab and Savage Lab developing CRISPR-Cas9 molecules with enhanced characteristics.